Midazolam as a first-line treatment for neonatal seizures: Retrospective study.

Détails

ID Serval
serval:BIB_ADB0C7B1BCAA
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Midazolam as a first-line treatment for neonatal seizures: Retrospective study.
Périodique
Pediatrics international
Auteur(s)
Dao K., Giannoni E., Diezi M., Roulet-Perez E., Lebon S.
ISSN
1442-200X (Electronic)
ISSN-L
1328-8067
Statut éditorial
Publié
Date de publication
05/2018
Peer-reviewed
Oui
Volume
60
Numéro
5
Pages
498-500
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Midazolam is commonly used to treat refractory seizures in newborns and as a first-line anti-epileptic drug in children. Its use as first-line treatment of neonatal seizures has not been investigated so far. We retrospectively studied the tolerability of midazolam in 72 newborn infants who received i.v. or i.n. midazolam as first-line treatment for seizures. No major side-effect exclusively due to midazolam was reported. The i.n. route was used for 20 patients (27.8%). Effectiveness could not be formally evaluated due to the absence of systematic electroencephalogram recording while midazolam was administered. In conclusion, midazolam was well-tolerated as a first-line abortive emergency treatment of neonatal seizure. The i.n. route offers a useful alternative to i.v. phenobarbital or phenytoin in emergency settings.
Mots-clé
anticonvulsant, infant, midazolam, neonatal seizure, phenobarbital
Pubmed
Web of science
Création de la notice
25/06/2018 10:55
Dernière modification de la notice
20/08/2019 15:17
Données d'usage